The pharmacogenomics of epilepsy
Valentina Franco1, Emilio Perucca1,2
1a 1 C. Mondino National Neurological Institute, Pavia, Italy.
Expert Review of Neurotherapeutics
|September 2, 2015
Summary
Genetic testing for antiepileptic drug (AED) response shows limited utility due to marker sensitivity. HLA-B*15:02 genotyping for carbamazepine adverse reactions is the most defined use, with others less compelling. Future applications in precision medicine are anticipated.
Area of Science:
- Pharmacogenomics
- Neurology
- Clinical Genetics
Background:
- Interindividual variability in antiepileptic drug (AED) response is significant.
- Current genetic markers for predicting AED response often lack sufficient sensitivity and specificity.
- The clinical utility of genetic testing in guiding AED therapy remains limited.
Purpose of the Study:
- To review the current state and limitations of genetic testing in guiding antiepileptic drug therapy.
- To identify established and emerging genetic markers associated with AED response and adverse reactions.
- To discuss the future potential of precision medicine in epilepsy treatment based on genetic insights.
Main Methods:
- Literature review of genetic markers and their association with AED efficacy and toxicity.
- Analysis of current clinical guidelines and recommendations for genetic testing in epilepsy.
- Evaluation of the sensitivity and specificity of key genetic tests, including HLA-B*15:02, HLA-A*31:01, and CYP2C9.
Main Results:
- HLA-B*15:02 genotyping is the most validated indication, particularly for South Asian ethnicities at risk for carbamazepine-induced severe cutaneous adverse reactions.
- Genetic testing for HLA-A*31:01 (carbamazepine) and CYP2C9 (phenytoin) has less compelling clinical indications currently.
- Most identified genetic markers have limited predictive value for general AED response.
Conclusions:
- Current genetic testing for AEDs has limited application, with specific genotyping for HLA-B*15:02 being the primary established indication.
- Further research into epilepsy gene function is crucial for advancing precision medicine in epilepsy treatment.
- The future of epilepsy management may involve targeted therapies based on individual genetic profiles to improve treatment outcomes.
Related Concept Videos
01:29Pharmacogenetics and Pharmacogenomics: Overview
151
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
151
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
112
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
112
01:27Pharmacogenetics of Drug Metabolism: Overview
118
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
118
01:29Pharmacogenomics: Identification of New Drug Targets
86
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
86
01:27Principles of Pharmacogenetics: Types of Genetic Variants
98
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
98
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
180
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
180